This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jul;14(7):392-393.

doi: 10.1038/nrclinonc.2017.85. Epub 2017 Jun 13.

Lung cancer: KEYNOTE-001 - combo improves melody

PMID: 28607520
DOI: 10.1038/nrclinonc.2017.85

Comment

Lung cancer: KEYNOTE-001 - combo improves melody

Diana Romero. Nat Rev Clin Oncol. 2017 Jul.

. 2017 Jul;14(7):392-393.

doi: 10.1038/nrclinonc.2017.85. Epub 2017 Jun 13.

Author

PMID: 28607520
DOI: 10.1038/nrclinonc.2017.85

No abstract available

PubMed Disclaimer

Comment on

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Shaverdian N, et al. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Lancet Oncol. 2017. PMID: 28551359 Free PMC article. Clinical Trial.

Similar articles

Keynote address on pathology of lung cancer.
Matthews MJ. Matthews MJ. Cancer Chemother Rep 3. 1973 Mar;4(2):15-6. Cancer Chemother Rep 3. 1973. PMID: 4729318 No abstract available.
Combo Therapy for Lung Cancer Extends Survival.
[No authors listed] [No authors listed] Cancer Discov. 2018 Jun;8(6):OF7. doi: 10.1158/2159-8290.CD-NB2018-051. Epub 2018 Apr 17. Cancer Discov. 2018. PMID: 29666060
The problem of cancer: lung cancer as a paradigm--keynote address summary.
Ruckdeschel JC. Ruckdeschel JC. Ethn Dis. 2005 Winter;15(1 Suppl 1):S1-2. Ethn Dis. 2005. PMID: 15787029 No abstract available.
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
Reck M. Reck M. Immunotherapy. 2018 Feb;10(2):93-105. doi: 10.2217/imt-2017-0121. Epub 2017 Nov 17. Immunotherapy. 2018. PMID: 29145737 Review.
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, Chinet T. Giroux Leprieur E, et al. Eur J Cancer. 2017 Jun;78:16-23. doi: 10.1016/j.ejca.2016.12.041. Epub 2017 Apr 11. Eur J Cancer. 2017. PMID: 28407528 Review.

See all similar articles

Cited by

Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.
Mireștean CC, Iancu RI, Iancu DT. Mireștean CC, et al. Curr Oncol. 2022 Oct 2;29(10):7388-7395. doi: 10.3390/curroncol29100580. Curr Oncol. 2022. PMID: 36290857 Free PMC article. Review.
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang D, Huang J, Zhang C, Guan Y, Guo Q. Zhang D, et al. Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):369-379. doi: 10.3779/j.issn.1009-3419.2019.06.07. Zhongguo Fei Ai Za Zhi. 2019. PMID: 31196371 Free PMC article. Review. Chinese.

References

1. Lancet Oncol. 2017 May 24;:null - PubMed

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information